FDA
-
-
-
-
-
-
-
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP)
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Corbus Pharma (CRBP): FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
-
-
-
-
-
-
-
Corbus Pharma (CRBP) Reports CRB-701 Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

